Navigation Links
CrossFire Beilstein Database Exceeds Ten Million Compounds
Date:8/20/2007

pularity of the database in China. "With pharmaceutical R&D services in China expanding at a rapid pace, easy access to high quality, experimental data on compounds and reactions is critical to success," says Dr. Hualiang Jiang, head of the Drug Discovery and Design Center, Shanghai Institute Materia Medica, Chinese Academy of Sciences. "The CrossFire Databases compile factual data about compounds and reactions from various publications into comprehensive overviews that accelerate discovery."

Since licensing the CrossFire databases in 2004, WuXi PharmaTech (NYSE: WX), the leading Chinese pharmaceutical and biotechnology R&D outsourcing company, has become the largest user of CrossFire Beilstein on CrossFire Direct.

"WuXi PharmaTech (NYSE: WX) relies on the high quality and relevance of the experimental data in CrossFire Beilstein," says Dr. Ge Li, CEO of WuXi PharmaTech. "The factual Beilstein database is an indispensable resource supporting WuXi PharmaTech's global pharmaceutical and biotechnology R&D outsourcing solutions."

CrossFire Beilstein is available online through CrossFire Commander, where the database is hosted on CrossFire Direct, or it is accessible via in-house hosting. Researchers can also access CrossFire Beilstein via DiscoveryGate(R), a comprehensive online cheminformatics content platform offered by MDL Information Systems Inc.

For information on searching reactions, substances and publications using CrossFire Beilstein, visit http://www.crossfirebeilstein.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with
'/>"/>

SOURCE Elsevier B V

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Stay out of crossfire when Midwest technology workers go to war
2. Medical College to build $6M transplant database
3. Alumni Association extends database help to university
4. Music, mail, databases and printing from a technologists desk
5. UW-Madison joins effort to build public pathogen bioinformatics database
6. OpGen Database Helps to Reduce Bioterrorist Threat
7. Catalyst International profit exceeds expectations
8. Venture Investors early-stage fund grows to $115 million
9. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
10. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
11. TomoTherapy raises $223 million in IPO
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Vermicompost from pig manure grows healthy hibiscus 2'Fighting' IED attacks with SCARE technology 2'Fighting' IED attacks with SCARE technology 3Study reveals H1N1 unexpected weakness 2Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 1Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 1VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 3VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 4VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 5VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 6VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 7VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 8VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 9New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 1New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 2